Atopic Dermatitis Market: Insights, Drivers, Barriers, Epidemiology Facts Report 2032

DelveInsight’s Atopic Dermatitis AD Market Insights report provides a thorough understanding of current treatment practices, emerging Atopic Dermatitis market share of the individual therapies, current and forecasted Atopic Dermatitis AD Market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).


Atopic Dermatitis Overview

Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of age much of the body may be affected. As children get older, the back of the knees and front of the elbows are the most common areas affected. In adults the hands and feet are the most commonly affected areas. Scratching worsens symptoms and affected people have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma.


Some of the keys of the Atopic Dermatitis AD Market report

Atopic dermatitis (AD) is the most common type of eczema. In fact, more than 18 million American adults have atopic dermatitis which often appears as a red, itchy rash normally on the cheeks, arms and legs.
As per Delveinsight’s analysis, adult females are affected more as compared to males, in case of AD.
The total atopic dermatitis diagnosed prevalent population in the United States was 25,091,967 in 2020.
Atopic dermatitis market companies are included like Regeneron Pharmaceuticals/Sanofi, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly, and many others.
Atopic dermatitis drugs are included like Dupilumab, Eucrisa, Corectim Ointment 0.5%, Olumiant, and many others.


Get Access to a Free Copy of Our Latest Sample Report @


Atopic Dermatitis Causes

Atopic eczema causes the skin to become itchy, dry, cracked and sore. Some people only have small patches of dry skin, but others may experience widespread inflamed skin all over the body. Inflamed skin can become red on lighter skin, and darker brown, purple or grey on darker skin. This can also be more difficult to see on darker skin. People with atopic eczema usually have periods when symptoms are less noticeable, as well as periods when symptoms become more severe (flare-ups).


Atopic Dermatitis Symptoms

AD presents different symptoms depending on the age of the person. Itching is the hallmark of AD; more than 85% of people with the condition experience this distressing symptom every day. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from compromised skin barrier leading to drier skin that is more prone to water loss and the entry of irritants. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions.


Atopic Dermatitis Diagnosis

At present, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.


Atopic Dermatitis Treatment

Currently, there is no cure for AD; however, it can be effectively managed with current treatment options. The pattern of the disease and its severity determine the kind of treatment the patient ought to receive. Treatment options include topical treatments like emollients, topical corticosteroids (TCS), antibiotics, topical calcineurin inhibitors (TCIs), and systemic treatment such as immunosuppressant, corticosteroids, and phototherapy. Drugs such as Eucrisa (Crisaborole), Dupixent (Dupilumab), Corectim ointment and Olumiant (baricitinib) are approved for AD.


Atopic Dermatitis AD Market Drivers

Rising prevalence of AD
Escalating expenditure on health care
Potential Emerging Therapies
Increasing awareness about the condition


Atopic Dermatitis AD Market Barriers

Over-the-counter medications
Outdated treatment recommendations
Poor prognosis and treatment adherence
Lack of timely diagnosis
Management of AD in the primary care setting


Atopic Dermatitis AD Market Report Scope

The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
Comprehensive insight has been provided into the Atopic Dermatitis (AD) epidemiology and treatment.
Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Dermatitis (AD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of Atopic Dermatitis (AD) market; historical and forecasted is included in the report, covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Atopic Dermatitis (AD) market.


Atopic Dermatitis Emerging Drugs

B244: AOBiome Therapeutics
Ly3650150: Eli Lilly and Company
Etrasimod: Arena Pharmaceuticals
FB825: Oneness Biotech


Atopic Dermatitis AD Market Companies

Regeneron Pharmaceuticals/Sanofi
Japan Tobacco and Torii Pharmaceutical
Eli Lilly
And many others


Atopic Dermatitis AD Market Drugs

Corectim Ointment 0.5%
And many others


View Detailed Research Report Here @


Table of content

Key Insights
Report Introduction
Executive Summary
Key Events
SWOT Analysis
Atopic Dermatitis Market Overview at a Glance
Disease Background and Overview
AD Clinical Guideline: American Academy of Dermatology Association (2014)
Atopic eczema in under 12s: Diagnosis and management by NICE (updated 2020)
Consensus-based European guidelines for the treatment of atopic eczema in adults and children (2018)
Treatment Algorithm
Epidemiology and Patient Population
Organizations contributing towards AD
Patient Journey
Marketed Drugs
Emerging Drugs
Potential of Current Therapies and Emerging Therapies
Atopic Dermatitis: Seven Major Market Analysis
Market Drivers
Market Barriers
Unmet Needs
KOL Views
Market Access and Reimbursement
DelveInsight Capabilities
About DelveInsight


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States